Truist Securities analyst Joon Lee raised the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $500.00 (from $360.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Praxis Precision Medicines (PRAX) call put ratio 1 call to 6 putsDecember 8, 2025 6:17 AM Piper Sandler on Praxis Precision Medicines (PRAX): 'Two Major Wins Set the Stage for Multiple Potential Approvals in 2026'December 5, 2025 7:20 AM Praxis Precision Medicines Inc. (PRAX) PT Raised to $303 at Deutsche BankDecember 5, 2025 7:09 AM Praxis Precision Medicines Inc. (PRAX) PT Raised to $304 at NeedhamDecember 5, 2025 7:07 AM Praxis Precision Medicines Inc. (PRAX) PT Raised to $340 at H.C. WainwrightDecember 5, 2025 6:44 AM After-hours movers: HPE, Ulta Beauty, SoFi, Rubrik and moreDecember 4, 2025 4:38 PM Praxis stops EMBOLD study early after relutrigine shows efficacyDecember 4, 2025 4:12 PM Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic EncephalopathiesDecember 4, 2025 4:10 PM Praxis receives FDA alignment on ulixacaltamide NDA submission plansDecember 4, 2025 4:01 PM Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential TremorDecember 4, 2025 4:01 PM